These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24881924)

  • 1. [Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].
    Honda Y; Inoue J; Shingaki S; Miyazaki K; Abe Y; Sekine E; Iki S; Tsukada N; Suzuki K
    Rinsho Ketsueki; 2014 May; 55(5):570-2. PubMed ID: 24881924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
    Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
    Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
    Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
    Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcutaneous bortezomib: a step towards optimised drug use.
    Mateos MV
    Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib and bilateral herpes zoster.
    di Meo N; Bergamo S; Dondas A; Trevisan G
    Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
    Honton B; Despas F; Dumonteil N; Rouvellat C; Roussel M; Carrie D; Galinier M; Montastruc JL; Pathak A
    Fundam Clin Pharmacol; 2014 Jun; 28(3):349-52. PubMed ID: 23781941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
    Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 14. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous bortezomib: in multiple myeloma.
    Hoy SM
    Drugs; 2013 Jan; 73(1):45-54. PubMed ID: 23338539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor for treatment of multiple myeloma.
    Ahmad K
    Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
    [No Abstract]   [Full Text] [Related]  

  • 17. The safety and efficacy of bortezomib in relapsed multiple myeloma.
    Jagannath S
    Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
    Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
    Zappasodi P; Dore R; Castagnola C; Astori C; Varettoni M; Mangiacavalli S; Lazzarino M; Corso A
    J Clin Oncol; 2007 Aug; 25(22):3380-1. PubMed ID: 17664489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.